Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Urogen Pharma Ltd
(NQ:
URGN
)
13.24
+0.39 (+3.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
272,413
Open
12.93
Bid (Size)
9.330 (1)
Ask (Size)
15.50 (1)
Prev. Close
12.85
Today's Range
12.67 - 13.37
52wk Range
8.690 - 24.13
Shares Outstanding
36,130,121
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 22, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024
May 13, 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
-12.95%
-12.95%
1 Month
-6.83%
-6.83%
3 Month
-22.53%
-22.53%
6 Month
+2.24%
+2.24%
1 Year
+7.73%
+7.73%
More News
Read More
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
May 13, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate at Upcoming Investor Conferences
May 07, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Outlook For UroGen Pharma
March 13, 2024
Via
Benzinga
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
May 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
May 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
May 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
April 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
April 15, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
April 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Via
Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023
March 14, 2024
Via
InvestorPlace
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
March 14, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
March 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For March 14, 2024
March 14, 2024
Via
Benzinga
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate at Upcoming Investor Conferences
February 01, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
January 24, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
January 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate in the B. Riley Healthcare Conference
January 11, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
December 07, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.